Myasthenia gravis
Rokowania, prognozy i postęp choroby
Myasthenia gravis (MG) to choroba autoimmunologiczna charakteryzująca się zmiennym osłabieniem mięśni i męczliwością, z typowym nasileniem w ciągu pierwszych 1-3 lat od rozpoznania. Większość pacjentów ma oczekiwaną długość życia porównywalną z populacją ogólną, jednak około 59% zgonów jest związanych z powikłaniami MG, głównie niewydolnością oddechową i podeszłym wiekiem. Początkowo około 80% pacjentów zgłasza objawy oczopochodne, takie jak diplopia i ptoza, a u 50% dochodzi do uogólnienia choroby w ciągu 2 lat. Czynniki rokownicze obejmują współistniejące choroby autoimmunologiczne, wiek zachorowania powyżej 40 lat, zmiany grasicy (hiperplazja, grasiczak), a także charakter początkowych objawów. Obecność grasiczaka i seronegatywność mogą predysponować do oporności na leczenie.
Myasthenia gravis – Rokowanie (przewidywanie wyników leczenia)
Myasthenia gravis (MG) jest chorobą autoimmunologiczną charakteryzującą się osłabieniem mięśni i męczliwością. Przebieg choroby ma charakter zmienny, co utrudnia prowadzenie kliniczne pacjentów. W ostatnich latach nastąpił znaczący postęp w zakresie prognozowania przebiegu choroby i określania rokowania u pacjentów z tą jednostką chorobową.1
Oczekiwana długość życia
Myasthenia gravis zasadniczo nie wpływa na oczekiwaną długość życia. Większość pacjentów z MG ma typową dla populacji ogólnej długość życia. Jednak w rzadkich przypadkach ciężkie powikłania, takie jak niewydolność oddechowa, mogą stanowić zagrożenie życia, szczególnie w pierwszych latach choroby.2
Badania sugerują, że około 59% osób z MG umiera z powodu powikłań związanych z chorobą. Dwoma głównymi czynnikami ryzyka zgonu z powodu MG są podeszły wiek i niewydolność oddechowa. Wczesne rozpoczęcie leczenia MG wiąże się z lepszym rokowaniem.3
Naturalny przebieg choroby
MG zazwyczaj osiąga największe nasilenie w ciągu pierwszych 1-3 lat od rozpoznania. Pacjenci mogą doświadczać okresów remisji, które mogą trwać nawet kilka lat. Przebieg choroby jest zazwyczaj zmienny, z okresami zaostrzeń i remisji.4
Około 80% pacjentów z MG początkowo zgłasza się z izolowanymi objawami oczopochodnymi – podwójnym widzeniem (diplopią) lub opadaniem powiek (ptozą). U około 50% z nich dochodzi do uogólnienia choroby w ciągu pierwszych 2 lat. Należy jednak zaznaczyć, że u około 50% pacjentów właściwa diagnoza nie zostaje postawiona w pierwszym roku występowania objawów.5
Czynniki prognostyczne
Zidentyfikowano szereg czynników klinicznych, które mogą służyć jako predyktory rokowania w MG:
- Współistniejące choroby autoimmunologiczne – obecność innych chorób autoimmunologicznych jest istotnym czynnikiem ryzyka nawrotu MG6
- Wiek zachorowania – późny wiek zachorowania (powyżej 40 lat) w ocznej postaci MG może przewidywać rozwój postaci uogólnionej7
- Zmiany grasicy – rozrost grasicy (hiperplazja) oraz grasiczak mogą być wskaźnikami uogólnienia w pierwszych sześciu miesiącach choroby89
- Początkowe objawy – ptoza lub diplopia, a także jednoczesne występowanie obu tych objawów, mogą służyć jako wskaźniki predykcyjne uogólnienia w pierwszych sześciu miesiącach lub w okresie 7-24 miesięcy od wystąpienia ocznej postaci MG10
- Obecność grasiczaka, seronegatywny status oraz choroby współistniejące mogą być związane z opornością na leczenie11
Modele predykcyjne w MG
W ostatnich latach opracowano kilka modeli predykcyjnych mających na celu prognozowanie przebiegu MG:
- Modele oparte na uczeniu maszynowym – umożliwiają prognozowanie krótkoterminowych wyników klinicznych u pacjentów z MG z różnymi typami przeciwciał. Takie narzędzia prognostyczne mogą pomóc w poprawie zarządzania klinicznego pacjentami z MG i utworzeniu systemu nadzoru dla specjalistów.12
- Bayesowski model predykcyjny – w przypadku ocznej postaci MG (OMG) opracowano model bayesowski oparty na rygorystycznych danych prospektywnych, który może służyć jako podstawa do przewidywania prawdopodobieństwa OMG. Model ten wykazał wyższą czułość (70-76%) w porównaniu do wcześniejszych badań (40-55%).1314
Wpływ leczenia na rokowanie
Wczesna interwencja może przynieść wymierne korzyści i szybką stabilizację w ciężkiej postaci choroby, co potwierdzają niektóre badania kliniczne. Dane długoterminowe wskazują, że choć u starszych pacjentów MG może mieć cięższy początek, to następnie wykazuje dobrą odpowiedź na leczenie.15
Tymektomia pozostaje kamieniem węgielnym leczenia MG u pacjentów z przeciwciałami przeciwko receptorom acetylocholiny (AChR). Postępy w technikach chirurgicznych, stratyfikacja pacjentów i lepsze zrozumienie patologii choroby będą nadal wpływać na wyniki leczenia pacjentów.16
Kierunki przyszłych badań
Przyszłe badania nad MG koncentrują się na czterech głównych obszarach, które mogą wpłynąć na rokowanie:17
- Ulepszenie diagnostyki laboratoryjnej w celu ułatwienia szybkiej diagnozy
- Skuteczne strategie ochrony nerwowo-mięśniowej
- Więcej badań i lepsze zrozumienie patofizjologii oraz odpowiedzi na leczenie u starszych osób
- Potencjalnie przełomowa rola terapii mających na celu uzyskanie trwałej odpowiedzi, takich jak komórki T z chimerycznym receptorem antygenu (CAR-T)
Trwające badania nad różnicami histologicznymi między pacjentami mogą w przyszłości przyczynić się do lepszej stratyfikacji pacjentów i prognozowania przebiegu choroby.18
Praktyczne wnioski dla klinicystów
Pomimo znaczących postępów w przewidywaniu przebiegu MG, ustalenie rozpoznania i określenie rokowania nadal wymaga doświadczenia klinicznego. Modele predykcyjne mogą pomóc w podejmowaniu decyzji klinicznych, ale nie zastępują kompleksowej oceny klinicznej.19
Opracowanie protokołów leczenia opartych na dowodach naukowych, szczególnie dla grup pacjentów o gorszym rokowaniu (np. osoby starsze z MG), stanowi jeden z głównych celów przyszłych badań, koncentrujących się na poprawie diagnostyki, prognozowania i leczenia w społeczności pacjentów z MG.20
Kolejne rozdziały
Zapraszamy do dalszego czytania naszego leksykonu.
Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.
Materiały źródłowe
- #1https://pmc.ncbi.nlm.nih.gov/articles/PMC9969443/
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatigability. The fluctuating nature of the disease course impedes the clinical management. […] The purpose of the study was to establish and validate a machine learning (ML) based model for predicting the short-term clinical outcome in MG patients with different antibody types. […] The explainable, ML-based predictive model can aid in forecasting the short-term outcome for MG with good accuracy in clinical practice. […] In current study, we have developed a short-term outcome prediction model using ML for MG patients with different antibody types. Our predictive tool may help promote the clinical management of MG patients and build a follow-up surveillance system for professionals.
- #2 Myasthenia Gravis Life Expectancy, Progression, and Outlookhttps://www.healthline.com/health/myasthenia-gravis/myasthenia-gravis-life-expectancy
Myasthenia gravis typically does not affect your life expectancy. But some severe complications, such as respiratory failure, can be life threatening, particularly in the early years of the disease. […] MG can affect the voluntary muscle movements you need for everyday activities. But the disease in itself is not deadly, and most people with MG have a typical life expectancy. […] In rare cases, MG may be life threatening. This is usually due to severe MG that affects the respiratory system. […] Overall, MG can become its most severe within 1-3 years. But you may also experience periods of remission, which can last several years at a time. […] Research suggests that 59% of people with MG die as a result of the disease. The two primary risk factors for death from MG are older age and respiratory failure. […] Generally, people with MG have the same life expectancy as people without it. […] The earlier you begin to treat MG, the better the overall outlook will be.
- #3 Myasthenia Gravis Life Expectancy, Progression, and Outlookhttps://www.healthline.com/health/myasthenia-gravis/myasthenia-gravis-life-expectancy
Myasthenia gravis typically does not affect your life expectancy. But some severe complications, such as respiratory failure, can be life threatening, particularly in the early years of the disease. […] MG can affect the voluntary muscle movements you need for everyday activities. But the disease in itself is not deadly, and most people with MG have a typical life expectancy. […] In rare cases, MG may be life threatening. This is usually due to severe MG that affects the respiratory system. […] Overall, MG can become its most severe within 1-3 years. But you may also experience periods of remission, which can last several years at a time. […] Research suggests that 59% of people with MG die as a result of the disease. The two primary risk factors for death from MG are older age and respiratory failure. […] Generally, people with MG have the same life expectancy as people without it. […] The earlier you begin to treat MG, the better the overall outlook will be.
- #4 Myasthenia Gravis Life Expectancy, Progression, and Outlookhttps://www.healthline.com/health/myasthenia-gravis/myasthenia-gravis-life-expectancy
Myasthenia gravis typically does not affect your life expectancy. But some severe complications, such as respiratory failure, can be life threatening, particularly in the early years of the disease. […] MG can affect the voluntary muscle movements you need for everyday activities. But the disease in itself is not deadly, and most people with MG have a typical life expectancy. […] In rare cases, MG may be life threatening. This is usually due to severe MG that affects the respiratory system. […] Overall, MG can become its most severe within 1-3 years. But you may also experience periods of remission, which can last several years at a time. […] Research suggests that 59% of people with MG die as a result of the disease. The two primary risk factors for death from MG are older age and respiratory failure. […] Generally, people with MG have the same life expectancy as people without it. […] The earlier you begin to treat MG, the better the overall outlook will be.
- #5https://journals.lww.com/10.1097/WNO.0000000000002346
Diagnosing ocular myasthenia gravis (OMG) remains challenging despite recent diagnostic advances. […] Approximately 80% of myasthenia patients first become symptomatic with isolated diplopia or ptosis and 50% generalize within 2 years. […] However, approximately 50% of patients do not receive the correct diagnosis within the first year of symptoms. […] Our prediction model serves as a basis to predict the OMG likelihood. […] The model was validated by determining the mean error rate and the area under the curve (AUC) by both 10-fold cross-validation and prediction on the retrospective USZ and UoT validation data consisting of 69 and 24 patients, respectively. […] The sensitivity was also lower in the validation data (USZ: 76%, UoT: 70%) but still significantly above the 40% and 55% reported in other studies.
- #6 Clinical predictors for the prognosis of myasthenia gravis | BMC Neurology | Full Texthttps://bmcneurol.biomedcentral.com/articles/10.1186/s12883-017-0857-7
Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis. […] Occurrence of associated autoimmune disease can serve as a potential predictor for myasthenia gravis relapse. Either ptosis or diplopia, as well as thymic hyperplasia can predict generalization in the first six months. […] The presence of concomitant autoimmune disease was identified to be a significant risk factor for MG relapse. Late age of OMG patients (40 years) at disease onset can predict the development of SGMG. Thymus hyperplasia and initial symptom ptosis or diplopia could serve as indicators for the generalization in the first six months. Concurrence of ptosis and diplopia was a useful predictor for generalization in 7-24 months after OMG onset. […] Our results suggested that late age of disease onset and thymus hyperplasia could predict the secondary generalization and the generalization time of OMG.
- #7 Clinical predictors for the prognosis of myasthenia gravis | BMC Neurology | Full Texthttps://bmcneurol.biomedcentral.com/articles/10.1186/s12883-017-0857-7
Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis. […] Occurrence of associated autoimmune disease can serve as a potential predictor for myasthenia gravis relapse. Either ptosis or diplopia, as well as thymic hyperplasia can predict generalization in the first six months. […] The presence of concomitant autoimmune disease was identified to be a significant risk factor for MG relapse. Late age of OMG patients (40 years) at disease onset can predict the development of SGMG. Thymus hyperplasia and initial symptom ptosis or diplopia could serve as indicators for the generalization in the first six months. Concurrence of ptosis and diplopia was a useful predictor for generalization in 7-24 months after OMG onset. […] Our results suggested that late age of disease onset and thymus hyperplasia could predict the secondary generalization and the generalization time of OMG.
- #8 Clinical predictors for the prognosis of myasthenia gravis | BMC Neurology | Full Texthttps://bmcneurol.biomedcentral.com/articles/10.1186/s12883-017-0857-7
Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis. […] Occurrence of associated autoimmune disease can serve as a potential predictor for myasthenia gravis relapse. Either ptosis or diplopia, as well as thymic hyperplasia can predict generalization in the first six months. […] The presence of concomitant autoimmune disease was identified to be a significant risk factor for MG relapse. Late age of OMG patients (40 years) at disease onset can predict the development of SGMG. Thymus hyperplasia and initial symptom ptosis or diplopia could serve as indicators for the generalization in the first six months. Concurrence of ptosis and diplopia was a useful predictor for generalization in 7-24 months after OMG onset. […] Our results suggested that late age of disease onset and thymus hyperplasia could predict the secondary generalization and the generalization time of OMG.
- #9 Clinical predictors for the prognosis of myasthenia gravis – PubMedhttps://pubmed.ncbi.nlm.nih.gov/28420327/
Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis. […] Occurrence of associated autoimmune disease can serve as a potential predictor for myasthenia gravis relapse. Either ptosis or diplopia, as well as thymic hyperplasia can predict generalization in the first six months.
- #10 Clinical predictors for the prognosis of myasthenia gravis | BMC Neurology | Full Texthttps://bmcneurol.biomedcentral.com/articles/10.1186/s12883-017-0857-7
Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis. […] Occurrence of associated autoimmune disease can serve as a potential predictor for myasthenia gravis relapse. Either ptosis or diplopia, as well as thymic hyperplasia can predict generalization in the first six months. […] The presence of concomitant autoimmune disease was identified to be a significant risk factor for MG relapse. Late age of OMG patients (40 years) at disease onset can predict the development of SGMG. Thymus hyperplasia and initial symptom ptosis or diplopia could serve as indicators for the generalization in the first six months. Concurrence of ptosis and diplopia was a useful predictor for generalization in 7-24 months after OMG onset. […] Our results suggested that late age of disease onset and thymus hyperplasia could predict the secondary generalization and the generalization time of OMG.
- #11https://link.springer.com/article/10.1007/s00415-025-12922-7
Early intervention could provide tangible benefits and rapid stabilization in severe disease, a concept we illustrate in Fig. 4, and in support of which there is some trial evidence. […] The presence of thymoma, seronegative status, and co-morbidities may be associated with refractory status although co-morbidities may be as much a result of drug regimens as a reason for non-responsive disease. […] Longitudinal data may provide a synthesis, delineating that, although there may be a more severe-onset in older-onset MG, it subsequently is highly responsive to treatment. […] The advancement of evidence-based treatment protocols for this group represents one of our four hopes for the future focusing on improving diagnosis, prognostication and treatment in the myasthenia community.
- #12https://pmc.ncbi.nlm.nih.gov/articles/PMC9969443/
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatigability. The fluctuating nature of the disease course impedes the clinical management. […] The purpose of the study was to establish and validate a machine learning (ML) based model for predicting the short-term clinical outcome in MG patients with different antibody types. […] The explainable, ML-based predictive model can aid in forecasting the short-term outcome for MG with good accuracy in clinical practice. […] In current study, we have developed a short-term outcome prediction model using ML for MG patients with different antibody types. Our predictive tool may help promote the clinical management of MG patients and build a follow-up surveillance system for professionals.
- #13https://journals.lww.com/10.1097/WNO.0000000000002346
Diagnosing ocular myasthenia gravis (OMG) remains challenging despite recent diagnostic advances. […] Approximately 80% of myasthenia patients first become symptomatic with isolated diplopia or ptosis and 50% generalize within 2 years. […] However, approximately 50% of patients do not receive the correct diagnosis within the first year of symptoms. […] Our prediction model serves as a basis to predict the OMG likelihood. […] The model was validated by determining the mean error rate and the area under the curve (AUC) by both 10-fold cross-validation and prediction on the retrospective USZ and UoT validation data consisting of 69 and 24 patients, respectively. […] The sensitivity was also lower in the validation data (USZ: 76%, UoT: 70%) but still significantly above the 40% and 55% reported in other studies.
- #14https://journals.lww.com/10.1097/WNO.0000000000002346
In conclusion, we developed and validated a Bayesian prediction model based on a rigorous prospective data set that can be used as a basis to predict the likelihood of OMG. However, establishing this diagnosis still requires clinical acumen. However, it can assist in clinical decision making on whether to diagnose seronegative OMG or consider an alternative etiology.
- #15https://link.springer.com/article/10.1007/s00415-025-12922-7
Early intervention could provide tangible benefits and rapid stabilization in severe disease, a concept we illustrate in Fig. 4, and in support of which there is some trial evidence. […] The presence of thymoma, seronegative status, and co-morbidities may be associated with refractory status although co-morbidities may be as much a result of drug regimens as a reason for non-responsive disease. […] Longitudinal data may provide a synthesis, delineating that, although there may be a more severe-onset in older-onset MG, it subsequently is highly responsive to treatment. […] The advancement of evidence-based treatment protocols for this group represents one of our four hopes for the future focusing on improving diagnosis, prognostication and treatment in the myasthenia community.
- #16https://link.springer.com/article/10.1007/s00415-025-12922-7
The last 10 years has brought transformative developments in the effective treatment of myasthenia gravis (MG). […] We close by expressing our four hopes for the next 510 years: improvements in laboratory medicine to facilitate rapid diagnosis, effective strategies for neuromuscular protection, more research into and better understanding of pathophysiology and treatment response in older individuals, and the potentially transformative role of therapies aimed at delivering a durable response such as chimeric antigen receptor (CAR) T cells. […] Ongoing research into histological differences between patients might advance patient stratification or prognostication in the future. […] In summary, thymectomy will certainly remain a cornerstone of MG management in patients with AChR antibodies. Advances in surgical techniques, patient stratification and disease pathology will continue to influence patient outcomes.
- #17https://link.springer.com/article/10.1007/s00415-025-12922-7
The last 10 years has brought transformative developments in the effective treatment of myasthenia gravis (MG). […] We close by expressing our four hopes for the next 510 years: improvements in laboratory medicine to facilitate rapid diagnosis, effective strategies for neuromuscular protection, more research into and better understanding of pathophysiology and treatment response in older individuals, and the potentially transformative role of therapies aimed at delivering a durable response such as chimeric antigen receptor (CAR) T cells. […] Ongoing research into histological differences between patients might advance patient stratification or prognostication in the future. […] In summary, thymectomy will certainly remain a cornerstone of MG management in patients with AChR antibodies. Advances in surgical techniques, patient stratification and disease pathology will continue to influence patient outcomes.
- #18https://link.springer.com/article/10.1007/s00415-025-12922-7
The last 10 years has brought transformative developments in the effective treatment of myasthenia gravis (MG). […] We close by expressing our four hopes for the next 510 years: improvements in laboratory medicine to facilitate rapid diagnosis, effective strategies for neuromuscular protection, more research into and better understanding of pathophysiology and treatment response in older individuals, and the potentially transformative role of therapies aimed at delivering a durable response such as chimeric antigen receptor (CAR) T cells. […] Ongoing research into histological differences between patients might advance patient stratification or prognostication in the future. […] In summary, thymectomy will certainly remain a cornerstone of MG management in patients with AChR antibodies. Advances in surgical techniques, patient stratification and disease pathology will continue to influence patient outcomes.
- #19https://journals.lww.com/10.1097/WNO.0000000000002346
In conclusion, we developed and validated a Bayesian prediction model based on a rigorous prospective data set that can be used as a basis to predict the likelihood of OMG. However, establishing this diagnosis still requires clinical acumen. However, it can assist in clinical decision making on whether to diagnose seronegative OMG or consider an alternative etiology.
- #20https://link.springer.com/article/10.1007/s00415-025-12922-7
Early intervention could provide tangible benefits and rapid stabilization in severe disease, a concept we illustrate in Fig. 4, and in support of which there is some trial evidence. […] The presence of thymoma, seronegative status, and co-morbidities may be associated with refractory status although co-morbidities may be as much a result of drug regimens as a reason for non-responsive disease. […] Longitudinal data may provide a synthesis, delineating that, although there may be a more severe-onset in older-onset MG, it subsequently is highly responsive to treatment. […] The advancement of evidence-based treatment protocols for this group represents one of our four hopes for the future focusing on improving diagnosis, prognostication and treatment in the myasthenia community.
Zobacz więcej
osłabienie mięśni choroba autoimmunologiczna niewydolność oddechowa model predykcyjny uogólnienie choroby choroby autoimmunologiczne uczenie maszynowe hiperplazja grasicy terapia CAR-T badanie histologiczne patofizjologia model bayesowski diplopia miastenia remisja stratyfikacja pacjentów postać uogólniona ptoza grasiczak tymektomia męczliwość mięśni oczna postać miastenii objawy oczne